SCHEDULE: Perceptive Advisors Discloses 2.4% Stake in Amicus
Ownership Disclosure
Perceptive Advisors and related entities report a 2.4% passive beneficial ownership in Amicus Therapeutics, Inc. common stock.
Summary
- Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. (collectively, the "Reporting Persons") beneficially own 7,412,830 shares of Amicus Therapeutics, Inc. Common Stock.
- This aggregate amount represents 2.4% of the Issuer's outstanding Common Stock.
- The ownership percentage is based on 308,239,374 shares of Common Stock outstanding as of July 25, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed on July 31, 2025.
- The Master Fund directly holds the 7,412,830 shares.
- Perceptive Advisors serves as the investment manager to the Master Fund and is deemed to beneficially own the shares.
- Joseph Edelman, as the managing member of Perceptive Advisors, is also deemed to beneficially own the shares.
- The Reporting Persons share both voting and dispositive power over all 7,412,830 shares.
Sentiment
Score: 5
Explanation: The filing is a neutral, routine disclosure of passive beneficial ownership, providing no positive or negative operational or financial news.
Future Outlook
This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the Issuer's operations or financial performance.
Industry Context
This filing represents a passive investment disclosure by an investment adviser specializing in life sciences, indicating a continued position in a biotechnology company. Such disclosures are routine for institutional investors maintaining significant, but non-controlling, stakes.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, confirming a passive investment stance by Perceptive Advisors.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which requires filing of this statement (beneficial ownership threshold) |
| 07/25/2025 | Date as of which 308,239,374 shares of Common Stock were outstanding |
| 07/31/2025 | Date Amicus Therapeutics, Inc. filed its Quarterly Report on Form 10-Q |
| 08/14/2025 | Date of filing of this Schedule 13G Amendment No. 5 |
Keywords
Amicus Therapeutics, Perceptive Advisors, Joseph Edelman, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Investment Management, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.